News

ELZA researchers report 12-month outcomes for a second-generation sub400 cross-linking protocol that extends CXL to ultra-thin keratoconus and post-LASIK ectasia corneas below 400 micrometres, halting progression in 76% of eyes while shortening treatment to about 18 minutes.
Categories: | |
Corneal imaging in keratoconus – Scheimpflug tomography, OCT and epithelial mapping – now catches the disease years earlier. How modern scans work, from ELZA.
Categories:
For two decades, one of the most quietly transformative treatments in eye care has rested on a deceptively simple idea: if you can stiffen the cornea, you can stop a sight-threatening disease in its tracks…
A new ELZA review in Die Ophthalmologie examines the mechanisms, clinical evidence, protocol selection, and indications for PACK-CXL in infectious keratitis.
Nikki and Farhad Hafezi represented ELZA at Vision China 2026, presenting work on keratoconus epidemiology, corneal cross-linking, K-MAP and international research collaboration.
The Second Global Consensus on Keratoconus and Ectatic Diseases was published today, and ELZA played a key role in its development.
Light for Sight returned to Bukhara to complete second-eye epi-on CXL treatment for two young girls with keratoconus identified through screening in Uzbekistan
Dr. Dion Paridaens, ELZA’s Consultant Oculoplastic and Orbital Surgeon, participated in the International Orbital Society Meeting 2026 in Amsterdam
Categories: | |
Dr Abha Gour from Dr Shroff’s Charity Eye Hospital visited ELZA to discuss visual rehabilitation in keratoconus, including ELZA-PACE and corneal wavefront-guided TransPRK.
Prof. Farhad Hafezi discusses ECO-CAIRS, a strategy using high-fluence CXL to optimise allogenic ring segments for keratoconus.
.
.